Most Read

Alvotech and Fuji Pharma recently announced an exclusive agreement for development and commercialization of biosimilars in Japan. Fuji´s investment into Alvotech further strengthens the partnership between the companies

Zirabev is a monoclonal antibody for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer

The product candidates include pemigatinib (FGFR1/2/3 inhibitor), itacitinib (JAK1 inhibitor) and parsaclisib (PI3Kδ inhibitor). Under the terms of the agreement, Innovent will pay Incyte US$40m in cash up

Targeting this biochemical pathway may help develop new therapies for alleviating the symptoms of anxiety disorders. The lab of Prof. Mike Fainzilber in the Institute’s Biomolecular Sciences Department

Black Diamond is the first company launched out of Ridgeline, Versant’s Discovery Engine based in Basel, Switzerland, and has a unique platform capable of prosecuting allosteric mutant oncogenes.

Under the agreement, the two companies will use e-therapeutics’ network-driven drug discovery platform for the identification of new therapeutics approaches to treat Type 2 diabetes, which currently accounts

The announcement is the latest in a series of strategic investments at PCI, demonstrating its market-leading presence in Biotech therapies, supporting medicines destined reach to more than 100

Jointly developed with Microsoft and powered by Azure, Adents Prodigi allows for secure data exchange and helps leverage the power of serialisation data to improve business practices. Cristers

The candidate, known as E2814, is an anti-tau monoclonal antibody set to be tested in human trials for the first time to assess its ability to slow the